Axovant Sciences Ltd. logo Axovant Sciences Ltd. Net Promoter Score 2018 Benchmarks

Estimated Net Promoter Score is

5

Axovant Sciences Ltd. is a clinical-stage pharmaceutical company that develops small molecule drugs to treat neurological disorders. The Hamilton, Bermuda-based company has offices in Basel, Switzerland and New York City and is traded on the New York Stock Exchange. The company was founded by former hedge fund manager Vivek Ramaswamy in 2014 as a wholly owned subsidiary of Roivant Sciences.

It held its IPO in 2015 and raised $315 million. Biotech analysts John Carroll of FierceBiotech and Adam Feuerstein of The Street noted that the IPO was overvalued based on the inexperience of the CEO and the low quality of its lead product, describing it as something that "GSK sold for lunch money".

As of 2015 the company's most advanced drug candidate was intepirdine, a potential add-on treatment to donepezil for patients with Alzheimer's disease and patients with dementia with Lewy bodies. Axovant acquired this molecule from GlaxoSmithKline in December 2014.

As of 2016 Axovant was also developing a second compound, nelotanserin. Axovant acquired global rights to nelotanserin from its former parent, Roivant, which had previously bought those rights from Arena Pharmaceuticals. As of 2016 Axovant was developing it as a treatment for Lewy body dementia

Quick facts about Axovant Sciences Ltd.

Key people Dr. David Hung (CEO)
Industry Biopharmaceutical
Founder Vivek Ramaswamy
Website axovant.com
Traded as NYSE: AXON

Net Promoter Score for Top Brands compared with Axovant Sciences Ltd.

NPS is a customer loyalty metric that measures customers’ willingness to not only return for another purchase or service but also make a recommendation to their family, friends or colleagues.

It is a powerful and effective technique, which can greatly increase a company's revenue if used properly.

The main advantages of NPS are close correlation with a company's growth and easy collection, interpretation and communication of the data.

Learn more about NPS

Yes, it is.

Net Promoter Score is a number from -100 from 100.

Scores higher than 0 are typically considered to be good and scores above 50 are considered to be excellent.

The industry average for Health Care / Major Pharmaceuticals is 0.



Browse NPS benchmarks

Customer.guru survey demo

important
How to understand the NPS benchmarks

The final Net Promoter Score of a company strongly depends on a context in which the satisfaction is measured.

Consider an example: If Axovant Sciences Ltd. sends out NPS surveys immediately after purchase, they are tracking their customers' initial excitement and the checkout experience.

On the other hand, if they survey their customers a few weeks after the purchase they are also tracking how satisfied their customers are with their products and services over time.

Therefore, comparing the NPS score of Axovant Sciences Ltd. with your own without any further context is not that useful.

What is extremely useful though, is using the NPS methodology to track the satisfaction of your customers over time. That's where Customer.guru comes in.

Learn more

Track Segmented Customer Satisfaction with Customer.guru

How are your customers satisfied depending on:

  • what products they purchased
  • when they placed their order
  • what number of orders they made?

    Sign up for free setup takes just 5 minutes

Other companies with Net Promoter Score similar to Axovant Sciences Ltd.

We have estimated the Net Promoter Score of Axovant Sciences Ltd. based on the publicly available information
including the sentiment of the company-related tweets, 3rd party reviews, and Alexa ratings.

Do you think this information is incorrect? Report incorrect information. Do you have more accurate data? Submit NPS score.